25 March 2025
Wellnex Life Limited
("Wellnex Life" or the "Company")
Issue of Equity - Pain Away vendor shares
Wellnex Life Limited (AIM: WNX | ASX: WNX), an innovative brand and distribution company focused on consumer health and wellness products, announces that application has been made for the admission to trading on AIM of 403,226 new ordinary shares of no par value ("Ordinary Shares") which have been issued in connection with the settlement of the deferred consideration which has been settled with the Pain Away vendors. The new Ordinary Shares will rank pari passu in all respects with the Company's issued Ordinary Shares and dealings are expected to commence on or around 26 March 2025.
Following Admission, the Company's issued share capital will comprise of 66,637,159 Ordinary Shares, none of which are held in treasury. Accordingly, the figure of 66,637,159 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules and the provisions of the Company's constitution.
Enquiries:
| Wellnex Life Limited | |
| | via Walbrook PR
|
| Strand Hanson Limited (Financial & Nominated Advisor) James Harris / Richard Johnson / Robert Collins | Tel: +44 (0)20 7409 3494 |
|
|
|
| Orana Corporate LLP (Joint Broker) |
|
| Sebastian Wykeham |
|
|
| |
| SP Angel Corporate Finance LLP (Joint Broker) | Tel: +44 (0)20 3470 0470 |
| David Hignell | |
|
| |
| Walbrook PR (UK Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or lifesciences@walbrookpr.com |
| Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893/+44 (0)7407 804 654 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
